½ÃÀ庸°í¼­
»óǰÄÚµå
1405894

´ã°ü ½ºÅÙÆ® ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® ¸®Æ÷Æ® : À¯Çüº°, ¿ëµµº°, ÃÖÁ¾ ¿ëµµº°, ºÎ¹®º° ¿¹Ãø(2024-2030³â)

Biliary Stents Market Size, Share & Trends Analysis Report By Type (Metal, Plastic), By Application (Bilio-pancreatic Leakages, Pancreatic Cancer), By End-use, And Segment Forecasts, 2024 - 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Grand View Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 110 Pages | ¹è¼Û¾È³» : 2-10ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

´ã°ü ½ºÅÙÆ® ½ÃÀåÀÇ ¼ºÀå°ú µ¿Çâ :

Grand View ResearchÀÇ ÃֽЏ®Æ÷Æ®¿¡ µû¸£¸é ¼¼°èÀÇ ´ã°ü ½ºÅÙÆ® ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 1¾ï 9,796¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù.

½ÃÀå ±Ô¸ð´Â 2024-2030³â ¿¬Æò±Õ 5.0%ÀÇ ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ ½ÃÀåÀº ´ãµµ Áúȯ°ú ¸¸¼º °£ ÁúȯÀÇ ¹ßº´·ü Áõ°¡¿¡ ÈûÀÔ¾î °­·ÂÇÑ ¼ºÀå¼¼¸¦ º¸À̰í ÀÖÀ¸¸ç, CDC º¸°í¼­¿¡ µû¸£¸é ¹Ì±¹¿¡¼­´Â ¸Å³â ¾à 25,000¸íÀÇ ³²¼º°ú 11,000¸íÀÇ ¿©¼ºÀÌ °£¾ÏÀ¸·Î ÀÎÇØ »ç¸ÁÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Áõ°¡ Ãß¼¼´Â ½ºÅÙÆ® À¯ÇüÀÇ ¹ßÀü, ³ëÀÎ Àα¸ Áõ°¡, ÇコÄɾ ´ëÇÑ ÀÎ½Ä Áõ°¡, ÃÖ¼Ò Ä§½ÀÀû Ä¡·á¿¡ ´ëÇÑ ¼±È£µµ Áõ°¡·Î ÀÎÇØ ´õ¿í °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù.

2023³â 4¿ù¿¡ ¹ßÇ¥µÈ NCBIÀÇ ³í¹®¿¡ µû¸£¸é ½ÃÀå È®´ë¿¡ ±â¿©ÇÏ´Â ¸Å¿ì Áß¿äÇÑ ¿äÀÎÀº ³»½Ã°æÀû ³»°­ ½ºÅÙÆ® »ðÀÔ¼ú(ELS)ÀÇ º¸±ÞÀ¸·Î, ELS´Â ¼ÒÈ­°üÀÇ ¾Ç¼º Æó»ö, ƯÈ÷ ´ãµµ Æó»öÀ» °ü¸®Çϱâ À§ÇÑ Àúħ½ÀÀûÀÌ°í ¸Å¿ì È¿°úÀûÀÎ ¼Ö·ç¼ÇÀ¸·Î µîÀåÇß½À´Ï´Ù. ¹æ»ç¼± Ä¡·á³ª ¼ö¼ú°ú °°Àº ±âÁ¸ Ä¡·á¹ýº¸´Ù ¿ì¼öÇϱ⠶§¹®¿¡ ¿ÏÄ¡ ¹× ½Åº¸Á¶¿ä¹ýÀÇ 1Â÷ ¼±ÅÃÀ¸·Î ÀÚ¸®¸Å±èÇϰí ÀÖ½À´Ï´Ù.

½ºÅÙÆ® À¯ÇüÀÌ ¿ªµ¿ÀûÀ¸·Î ÁøÈ­Çϰí, ³ôÀº È¿´É, ¾ÈÀü¼º, ÷´Ü ±â¼ú¿¡ ´ëÇÑ ÀûÀÀ¼ºÀÌ ¿ä±¸µÇ¸é¼­ ½ºÅÙÆ® ½ÃÀåÀÇ Áö¼ÓÀûÀÎ ¼ºÀå°ú °ü·Ã¼ºÀ» ÃËÁøÇÏ´Â Ã˸ÅÁ¦ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±àÁ¤ÀûÀÎ Ãß¼¼¿¡µµ ºÒ±¸Çϰí, COVID-19 ÆÒµ¥¹ÍÀ¸·Î ÀÎÇÑ ¾Ï °ËÁø °¨¼Ò·Î ÀÎÇØ ½Å±Ô ¾Ï Áø´Ü °Ç¼ö°¡ ´«¿¡ ¶ç°Ô °¨¼ÒÇÏ´Â µî ¾î·Á¿òÀÌ ¹ß»ýÇϰí ÀÖ½À´Ï´Ù.

´ã°ü ½ºÅÙÆ® ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

  • 2023³â ºÏ¹Ì°¡ 43.69%·Î °¡Àå Å« ¸ÅÃâ Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ÀÌ Áö¿ªÀÇ Ã·´ÜÈ­µÈ ÀÇ·á ÀÎÇÁ¶ó, ¼ÒÈ­±â °Ç°­¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡, °í·ÉÈ­ Àα¸ Áõ°¡°¡ ½ÃÀå ¿ìÀ§¸¦ Á¡ÇÏ´Â µ¥ ±â¿©Çϰí ÀÖ½À´Ï´Ù.
  • À¯Çüº°·Î´Â ±Ý¼Ó ºÎ¹®ÀÌ 2023³â 66.99%ÀÇ ¸ÅÃâ Á¡À¯À²·Î ´ã°ü ½ºÅÙÆ® »ê¾÷À» Áö¹èÇß½À´Ï´Ù. ±Ý¼ÓÀÇ ¼ºÀåÀº ¿ÏÀü ÇǺ¹ ÀÚ±â È®ÀåÇü ±Ý¼Ó ½ºÅÙÆ®(FCSEMS)ÀÇ ÃâÇö¿¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù.
  • ¿ëµµº°·Î´Â ´ã¼® ºÎ¹®ÀÌ 2023³â 41.28%ÀÇ ¸ÅÃâ Á¡À¯À²·Î ½ÃÀåÀ» Àå¾ÇÇß½À´Ï´Ù. ÀÌ·¯ÇÑ ¼ºÀåÀÇ ÁÖ¿ä ¿øµ¿·ÂÀº ´ã¼® °ü·Ã ÁúȯÀÇ À¯º´·ü Áõ°¡·Î ÀÎÇØ È¿°úÀûÀ̰í ÃÖ¼Ò Ä§½ÀÀûÀÎ °³ÀÔ¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.
  • ÃÖÁ¾ ¿ëµµº°·Î´Â º´¿ø ºÎ¹®ÀÌ 74.23%ÀÇ ¸ÅÃâ Á¡À¯À²·Î ½ÃÀåÀ» Àå¾ÇÇß½À´Ï´Ù. º´¿øÀº ÁÖ·Î Á¾ÇÕÀûÀÎ ÀÇ·á ¼­ºñ½º¸¦ Á¦°øÇÏ´Â ÁÖ¿ä ¼¾Åͷμ­ ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ´ã°ü ½ºÅÙÆ® ½ÃÀå º¯¼ö, µ¿Çâ, ¹üÀ§

  • ½ÃÀå °èÅë Àü¸Á
    • ¸ð½ÃÀå Àü¸Á
    • °ü·Ã/ºÎ¼ö ½ÃÀå Àü¸Á
  • ½ÃÀå ¿ªÇÐ
    • ½ÃÀå ÃËÁø¿äÀÎ ºÐ¼®
    • ½ÃÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
  • ´ã°ü ½ºÅÙÆ® ½ÃÀå ºÐ¼® Åø
    • ¾÷°è ºÐ¼® - PorterÀÇ »ê¾÷ ºÐ¼®
    • PESTEL ºÐ¼®

Á¦4Àå ´ã°ü ½ºÅÙÆ® ½ÃÀå : À¯Çü ÃßÁ¤¡¤µ¿Ç⠺м®

  • Á¤ÀÇ¿Í ¹üÀ§
  • À¯Çü ½ÃÀå Á¡À¯À², 2023³â ¹× 2030³â
  • ºÎ¹® ´ë½Ãº¸µå
  • À¯Çüº° ¼¼°èÀÇ ´ã°ü ½ºÅÙÆ® ½ÃÀå Àü¸Á
  • ÀÌÇÏ ½ÃÀå ±Ô¸ð, ¿¹Ãø ¹× µ¿Ç⠺м®, 2018-2030³â
    • ±Ý¼Ó
    • Æú¸®¸Ó
    • ÇÃ¶ó½ºÆ½

Á¦5Àå ´ã°ü ½ºÅÙÆ® ½ÃÀå : ¿ëµµ ÃßÁ¤¡¤µ¿Ç⠺м®

  • Á¤ÀÇ¿Í ¹üÀ§
  • ¿ëµµ ½ÃÀå Á¡À¯À², 2023³â°ú 2030³â
  • ºÎ¹® ´ë½Ãº¸µå
  • ¿ëµµº° ¼¼°èÀÇ ´ã°ü ½ºÅÙÆ® ½ÃÀå Àü¸Á
  • ÀÌÇÏ ½ÃÀå ±Ô¸ð, ¿¹Ãø ¹× µ¿Ç⠺м®, 2018-2030³â
    • ´ãÃé´©Ãâ
    • ÃéÀå¾Ï
    • ¾ç¼º ´ã°ü ±¸Á¶
    • ´ã¼®
    • ±âŸ

Á¦6Àå ´ã°ü ½ºÅÙÆ® ½ÃÀå : ÃÖÁ¾ ¿ëµµ ÃßÁ¤¡¤µ¿Ç⠺м®

  • Á¤ÀÇ¿Í ¹üÀ§
  • ÃÖÁ¾ ¿ëµµ ½ÃÀå Á¡À¯À², 2023³â ¹× 2030³â
  • ºÎ¹® ´ë½Ãº¸µå
  • ÃÖÁ¾ ¿ëµµº° ¼¼°èÀÇ ´ã°ü ½ºÅÙÆ® ½ÃÀå Àü¸Á
  • ÀÌÇÏ ½ÃÀå ±Ô¸ð, ¿¹Ãø ¹× µ¿Ç⠺м®, 2018-2030³â
    • º´¿ø
    • ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ
    • ±âŸ

Á¦7Àå ´ã°ü ½ºÅÙÆ® ½ÃÀå : Áö¿ª ÃßÁ¤¡¤µ¿Ç⠺м®

  • Áö¿ª ½ÃÀå Á¡À¯À² ºÐ¼®, 2023³â ¹× 2030³â
  • Áö¿ª ½ÃÀå ´ë½Ãº¸µå
  • ¼¼°èÀÇ Áö¿ª ½ÃÀå ½º³À¼ô
  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø µ¿Ç⠺м®, 2018-2030³â :
  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • ¿µ±¹
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ³ë¸£¿þÀÌ
    • ½º¿þµ§
    • µ§¸¶Å©
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ÀϺ»
    • Áß±¹
    • Àεµ
    • È£ÁÖ
    • Çѱ¹
    • ű¹
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ¾Æ¸£ÇîÆ¼³ª
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®
    • Äí¿þÀÌÆ®

Á¦8Àå °æÀï ±¸µµ

  • ÁÖ¿ä ½ÃÀå Âü¿© ±â¾÷¿¡ ÀÇÇÑ ÃÖ±Ù µ¿Çâ°ú ¿µÇ⠺м®
  • ȸ»ç/°æÀï ºÐ·ù
    • À̳뺣ÀÌÅÍ
  • º¥´õ ±¸µµ
    • ÁÖ¿ä À¯Åë¾÷ü¿Í ä³Î ÆÄÆ®³Ê ¸®½ºÆ®
    • ÁÖ¿ä °í°´
    • ÁÖ¿ä ±â¾÷ Á¡À¯À² ºÐ¼®, 2023³â
    • Boston Scientific
    • Boston Scientific
    • Cook Group
    • ENDO-FLEX GmbH
    • Olympus Corporation
    • B Braun Melsungen
    • CONMED Corporation
    • MI Tech
    • CRBard(Becton, Dickinson &Company)
    • Medtronic plc
    • Cardinal Health
    • Merit Medical System
KSA 24.01.26

Biliary Stents Market Growth & Trends:

The global biliary stents market size is estimated to reach USD 197.96 million by 2030, based on a new report by Grand View Research, Inc. The market is projected to grow at a CAGR of 5.0% from 2024 to 2030. The market is experiencing robust growth, driven by the escalating incidence of biliary disorders and chronic liver diseases. In the U.S., liver cancer annually affects around 25,000 men and 11,000 women, resulting in a substantial mortality rate, according to the CDC report. This upward trajectory is further propelled by advancements in stent types, a growing geriatric population, heightened healthcare awareness, and a rising preference for minimally invasive procedures.

According to the NCBI article published in April 2023, a pivotal factor contributing to market expansion is the widespread adoption of endoscopic luminal stenting (ELS). ELS has emerged as a minimally invasive and highly effective solution for managing malignant obstructions in the gastrointestinal tract, particularly biliary obstructions. Its superiority over traditional modalities like radiotherapy and surgery positions it as a preferred first-line application in palliative and neoadjuvant settings.

The dynamic evolution of stent types, addressing the demand for heightened efficacy, safety, and adaptability to cutting-edge technologies, serves as a catalyst for the continued growth and relevance of the market. Despite these positive trends, the impact of reduced cancer screening initiatives during the COVID-19 pandemic has introduced challenges, leading to a notable decline in newly diagnosed cancer cases.

Biliary Stents Market Report Highlights:

  • In 2023, North America held the market's largest revenue share of 43.69%. The region's advanced healthcare infrastructure, increasing awareness about gastrointestinal health, and a growing aging population contribute to the market's dominance
  • Based on type, the metal segment dominated the biliary stents industry with a revenue share of 66.99% in 2023. The growth of metal is propelled by the advent of fully covered self-expandable metal stents (FCSEMS)
  • Based on application, the gallstones segment dominated the market with a revenue share of 41.28% in 2023. A significant driving force in this expansion is the increasing prevalence of gallstone-related conditions, prompting a growing demand for effective and minimally invasive interventions
  • In terms of end-use, the hospitals segment dominated the market with a revenue share of 74.23%. Hospitals primarily contribute to the market growth serving as prime centers for comprehensive medical care

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Type
    • 1.1.2. Application
    • 1.1.3. End-use
    • 1.1.4. Regional scope
    • 1.1.5. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
      • 1.3.5.1. Data for primary interviews in North America
      • 1.3.5.2. Data for primary interviews in Europe
      • 1.3.5.3. Data for primary interviews in Asia Pacific
      • 1.3.5.4. Data for primary interviews in Latin America
      • 1.3.5.5. Data for Primary interviews in MEA
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity flow analysis (Model 1)
    • 1.6.2. Approach 1: Commodity flow approach
    • 1.6.3. Volume price analysis (Model 2)
    • 1.6.4. Approach 2: Volume price analysis
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Type outlook
    • 2.2.2. Application outlook
    • 2.2.3. End-use outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Biliary Stents Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising incidence of biliary disorders and chronic liver diseases
      • 3.2.1.2. Advancements for stent type
      • 3.2.1.3. Growing geriatric population and healthcare awareness
      • 3.2.1.4. Increasing minimally invasive procedures
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High cost of the plastic bile duct stents
      • 3.2.2.2. Complications and risk related to bile duct stents
  • 3.3. Biliary Stents Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Biliary Stents Market: Type Estimates & Trend Analysis

  • 4.1. Definitions and Scope
    • 4.1.1. Metal
    • 4.1.2. Polymer
    • 4.1.3. Plastic
  • 4.2. Type Market Share, 2023 & 2030
  • 4.3. Segment Dashboard
  • 4.4. Global Biliary Stents Market by Type Outlook
  • 4.5. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.5.1. Metal
      • 4.5.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.2. Polymer
      • 4.5.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.3. Plastic
      • 4.5.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Biliary Stents Market: Application Estimates & Trend Analysis

  • 5.1. Definitions and Scope
    • 5.1.1. Bilio-pancreatic Leakages
    • 5.1.2. Pancreatic Cancer
    • 5.1.3. Benign Biliary Structures
    • 5.1.4. Gallstones
    • 5.1.5. Others
  • 5.2. Application Market Share, 2023 & 2030
  • 5.3. Segment Dashboard
  • 5.4. Global Biliary Stents Market by Application Outlook
  • 5.5. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.5.1. Bilio-pancreatic Leakages
      • 5.5.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.5.2. Pancreatic Cancer
      • 5.5.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.5.3. Benign Biliary Structures
      • 5.5.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.5.4. Gallstones
      • 5.5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.5.5. Others
      • 5.5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Biliary Stents Market: End-use Estimates & Trend Analysis

  • 6.1. Definitions and Scope
    • 6.1.1. Hospitals
    • 6.1.2. Ambulatory Surgical Centers
    • 6.1.3. Others
  • 6.2. End-use Market Share, 2023 & 2030
  • 6.3. Segment Dashboard
  • 6.4. Global Biliary Stents Market by End-use Outlook
  • 6.5. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 6.5.1. Hospitals
      • 6.5.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.2. Ambulatory Surgical Centers
      • 6.5.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.3. Others
      • 6.5.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Biliary Stents Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2023 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Global Regional Market Snapshot
  • 7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.5. North America
    • 7.5.1. U.S.
      • 7.5.1.1. U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. Canada
      • 7.5.2.1. Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.6. Europe
    • 7.6.1. UK
      • 7.6.1.1. UK market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. Germany
      • 7.6.2.1. Germany market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. France
      • 7.6.3.1. France market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. Italy
      • 7.6.4.1. Italy market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. Spain
      • 7.6.5.1. Spain market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.6.6. Norway
      • 7.6.6.1. Norway market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.6.7. Sweden
      • 7.6.7.1. Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.6.8. Denmark
      • 7.6.8.1. Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.7. Asia Pacific
    • 7.7.1. Japan
      • 7.7.1.1. Japan market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.7.2. China
      • 7.7.2.1. China market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.7.3. India
      • 7.7.3.1. India market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.7.4. Australia
      • 7.7.4.1. Australia market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.7.5. South Korea
      • 7.7.5.1. South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.7.6. Thailand
      • 7.7.6.1. Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.8. Latin America
    • 7.8.1. Brazil
      • 7.8.1.1. Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.8.2. Mexico
      • 7.8.2.1. Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.8.3. Argentina
      • 7.8.3.1. Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.9. MEA
    • 7.9.1. South Africa
      • 7.9.1.1. South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.9.2. Saudi Arabia
      • 7.9.2.1. Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.9.3. UAE
      • 7.9.3.1. UAE market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.9.4. Kuwait
      • 7.9.4.1. Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
    • 8.2.1. Innovators
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company market share analysis, 2023
    • 8.3.4. Boston Scientific
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. Cook Group
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Product benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. ENDO-FLEX GmbH
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Product benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. Olympus Corporation
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Product benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. B Braun Melsungen
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Product benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. CONMED Corporation
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Product benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. M.I Tech
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Product benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. C.R.Bard (Becton, Dickinson & Company)
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Product benchmarking
      • 8.3.11.4. Strategic initiatives
    • 8.3.12. Medtronic plc
      • 8.3.12.1. Company overview
      • 8.3.12.2. Financial performance
      • 8.3.12.3. Product benchmarking
      • 8.3.12.4. Strategic initiatives
    • 8.3.13. Cardinal Health
      • 8.3.13.1. Company overview
      • 8.3.13.2. Financial performance
      • 8.3.13.3. Product benchmarking
      • 8.3.13.4. Strategic initiatives
    • 8.3.14. Merit Medical System
      • 8.3.14.1. Company overview
      • 8.3.14.2. Financial performance
      • 8.3.14.3. Product benchmarking
      • 8.3.14.4. Strategic initiatives
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦